Description
Teclistamab-cqyv is used in the treatment of relapsed or refractory multiple myeloma and has shown efficacy in clinical trials, but it is not currently indicated for colorectal cancer. Its mechanism does not target pathways typically involved in colorectal carcinogenesis.
Mechanism of Action
Teclistamab-cqyv is a bispecific antibody that binds to both CD3 and BCMA (B-cell maturation antigen) receptors, facilitating the interaction between T cells and malignant plasma cells.
Side Effects
Hematological toxicity; cytokine release syndrome; infections; neurotoxicity
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT07463599
Phase 1
Recruiting
Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma
United States
NCT04851119
Phase 1
Recruiting
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
United States